08:00 , Dec 15, 2008 |  BioCentury  |  Finance

Ebb & Flow

In good economic times, companies that run into problems can often avoid tough decisions - such as dropping programs or employees, or shutting their doors - by raising money from less savvy investors. Meanwhile, disgruntled...
07:00 , May 12, 2008 |  BC Week In Review  |  Company News

Inovio board of directors update

Inovio Biomedical Corp. (AMEX:INO), San Diego, Calif.   Business: Drug delivery, Cancer   Appointed: Patrick Gan, managing partner of ATP Capital  ...
07:00 , May 16, 2005 |  BioCentury  |  Finance

Ebb & Flow

The Bank of New York has seen a big increase in the number of ex-U.S. biotech companies seeking Level I ADRs in order to get access to U.S. investors. The move is most likely being...
07:00 , Jul 19, 2004 |  BioCentury  |  Finance

Ebb & Flow

Last week's earnings announcement from Johnson & Johnson (JNJ) again showed a declining trajectory for its EPO products, reflecting competition from Aranesp from Amgen (AMGN). Indeed, JNJ's Procrit / Eprex drugs showed a steeper sales...
07:00 , Jul 14, 2004 |  BC Extra  |  Financial News

Trubion raises $32 million

Trubion (Seattle, Wash.) raised $32 million in a series B round co-led by Prospect and Venrock. Other investors in the inflammatory disease and cancer company included Arch; Frazier; Oxford Bioscience; and ATP Capital. David Schnell,...
08:00 , Nov 25, 2002 |  BioCentury  |  Finance

Ebb & Flow

Talent continues to slip out of Immunex since its takeover by Amgen (AMGN) earlier this year. Ken Mohler, Immunex's former vice president for biology, last week secured $13.6 million in venture financing for GeneCraft ,...
08:00 , Nov 20, 2002 |  BC Extra  |  Financial News

GeneCraft raises $13.6 million

GeneCraft (Seattle, Wash.) raised $13.6 million in its first venture round co-led by ARCH Venture Partners; Frazier Healthcare Ventures; and Oxford Bioscience Partners. Other investors included Cascade Investments and ATP Capital. Co-founder Peter Thompson is...
08:00 , Feb 25, 2002 |  BC Extra  |  Financial News

Agilix closes $28 million round

Agilix (New Haven, Conn.), which is developing its Faast technology for whole-genome transcription analysis, raised $7.2 million in a second closing of its series B round. The sale brings to $28 million the total raised...
08:00 , Dec 17, 2001 |  BC Extra  |  Financial News

Agilix raises $20.8 million

Functional genomics and proteomics play Agilix (New Haven, Conn.) raised $20.8 million in a private financing. Investors included Burrill & Co.; Hambrecht & Quist Capital Management; Stephens Group; Wheatley MedTech Partners; BioVeda; and ATP Capital....